表紙
市場調査レポート

勃起不全:パイプライン分析

Erectile Dysfunction - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232812
出版日 ページ情報 英文 121 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
勃起不全:パイプライン分析 Erectile Dysfunction - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 121 Pages
概要

勃起不全(ED)とは、男性が性交渉に必要なだけの勃起を維持できない障害を指し、また性向不能症とも呼ばれています。疾病素質には血縁や体重過剰、傷害、麻薬・アルコール摂取、薬物療法(抗うつ剤・抗ヒスタミン剤・高血圧治療薬・鎮痛剤・前立腺がん治療薬ほか)などが含まれています。

当レポートでは、世界各国での勃起不全(ED)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

勃起不全(ED)の概要

治療薬の開発

  • 勃起不全向けパイプライン製品:概要
  • 勃起不全向けパイプライン製品:比較分析

各企業で開発中の勃起不全治療薬

大学/研究機関で研究中の勃起不全治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

勃起不全治療薬:開発中の製品の一覧(企業別)

勃起不全治療薬:研究中の製品の一覧(大学/研究機関別)

勃起不全治療薬の開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Apricus Biosciences, Inc.
  • Biopharm GmbH
  • Corridor Pharmaceuticals Inc.
  • Futura Medical Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humanetics Corporation
  • IntelGenx Corp.
  • Mezzion Pharma Co. Ltd.
  • 田辺三菱製薬
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Pacific Therapeutics Ltd.
  • Palatin Technologies, Inc.
  • Pharmicell Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Suda Ltd
  • U.S. Stem Cell, Inc.
  • Yungjin Pharm. Co., Ltd.

勃起不全:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (PDE-5 阻害剤 + 塩酸トラマドール)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • AdipoCell
  • alprostadil
  • AP-102
  • avanafil
  • BIO-300
  • BL-214
  • cimaglermin alfa
  • fadanafil
  • HCP-1302
  • HCP-1303
  • Immpocellgram
  • MED-2005
  • ニトログリセリン
  • 心血管疾患・代謝異常・勃起不全治療用 Gタンパク質共役受容体Mas活性ペプチド
  • 変性円板疾患・骨折・パーキンソン病・勃起不全治療用合成タンパク質
  • クエン酸シルデナフィル
  • 血管機能不全・ PAH・勃起不全治療用アルギナーゼ阻害剤
  • 勃起不全治療用 PDE5阻害薬
  • SUD-003
  • 女性の性機能障害・勃起不全治療用メラノコルチン4受容体作動合成ペプチド
  • T-6932
  • tadalafil
  • TF-0092
  • TPN-171
  • TPN-729
  • TR-399
  • udenafil
  • VLFIA-330
  • YBH-1603

勃起不全治療薬:パイプライン製品の最新動向

勃起不全治療薬:開発が休止状態の製品

勃起不全治療薬:開発が中止された製品

勃起不全関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7645IDB

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2016', provides an overview of the Erectile Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
  • The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
  • The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Erectile Dysfunction Overview
  • Therapeutics Development
    • Pipeline Products for Erectile Dysfunction - Overview
    • Pipeline Products for Erectile Dysfunction - Comparative Analysis
  • Erectile Dysfunction - Therapeutics under Development by Companies
  • Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes
  • Erectile Dysfunction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Erectile Dysfunction - Products under Development by Companies
  • Erectile Dysfunction - Products under Investigation by Universities/Institutes
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
    • Acorda Therapeutics, Inc.
    • Apricus Biosciences, Inc.
    • Biopharm GmbH
    • Corridor Pharmaceuticals Inc.
    • Futura Medical Plc
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Humanetics Corporation
    • IntelGenx Corp.
    • Mezzion Pharma Co. Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • Monosol Rx, LLC
    • NAL Pharmaceuticals Ltd.
    • Pacific Therapeutics Ltd.
    • Palatin Technologies, Inc.
    • Pharmicell Co., Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Suda Ltd
    • U.S. Stem Cell, Inc.
    • Yungjin Pharm. Co., Ltd.
  • Erectile Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avanafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cimaglermin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1302 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1303 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Immpocellgram - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MED-2005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nitroglycerin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUD-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-6932 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TF-0092 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPN-171 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPN-729 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TR-399 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VLFIA-330 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YBH-1603 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Erectile Dysfunction - Recent Pipeline Updates
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
      • Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
      • Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting
      • Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity
      • Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
      • Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology
      • Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product
      • Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
      • Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil
      • Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Erectile Dysfunction, H1 2016
  • Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Erectile Dysfunction - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H1 2016
  • Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2016
  • Erectile Dysfunction - Pipeline by Corridor Pharmaceuticals Inc., H1 2016
  • Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2016
  • Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Humanetics Corporation, H1 2016
  • Erectile Dysfunction - Pipeline by IntelGenx Corp., H1 2016
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H1 2016
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Pacific Therapeutics Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H1 2016
  • Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Erectile Dysfunction - Pipeline by Suda Ltd, H1 2016
  • Erectile Dysfunction - Pipeline by U.S. Stem Cell, Inc., H1 2016
  • Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Erectile Dysfunction Therapeutics - Recent Pipeline Updates, H1 2016
  • Erectile Dysfunction - Dormant Projects, H1 2016
  • Erectile Dysfunction - Dormant Projects (Contd..1), H1 2016
  • Erectile Dysfunction - Dormant Projects (Contd..2), H1 2016
  • Erectile Dysfunction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Erectile Dysfunction, H1 2016
  • Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top